Human MLL-AF9 Overexpression Induces Aberrant Hematopoietic Expansion in Zebrafish

Figure 3

Doxorubicin inhibition of MLL-AF9-induced hematopoiesis. Doxorubicin and DMSO (control) were administered to MLL-AF9-injected and wild-type embryos from 24 to 48hpf. WISH assays of the (a) definitive hematopoietic stem cell marker c-myb and (b–d) myeloid lineage markers mpo, lyz, and l-plastin in wild-type embryos treated with DMSO (top), MLL-AF9-injected embryos treated with DMSO (middle), and MLL-AF9-injected embryos treated with doxorubicin (bottom) at 48hpf. (e) Relative expression of the marker genes for definitive hematopoiesis (runx1 and c-myb) and myeloid hematopoiesis (l-plastin, csf1r, mfap4, mpo, and lyz) in wild-type and MLL-AF9-injected embryos treated with DMSO or doxorubicin analyzed by qRT-PCR. Wild-type embryos treated with DMSO were used as a control.

(a)

(b)

(c)

(d)

(e)